Grifols Q1 2025: Revenue Up 7.4%, EBITDA Up 14.2%
Ticker: GIKLY · Form: 6-K · Filed: May 12, 2025 · CIK: 1438569
| Field | Detail |
|---|---|
| Company | Grifols SA (GIKLY) |
| Form Type | 6-K |
| Filed Date | May 12, 2025 |
| Risk Level | low |
| Sentiment | bullish |
Sentiment: bullish
Topics: earnings, revenue-growth, biopharma, cash-flow
TL;DR
Grifols crushed Q1 2025: revenues +7.4% to €1.79B, Adj EBITDA +14.2%, free cash flow up €209M. Strong Biopharma.
AI Summary
Grifols, S.A. reported strong first quarter 2025 results on May 12, 2025. Net revenues increased by 7.4% to EUR 1,786 million, driven by Biopharma's 6.6% growth. Adjusted EBITDA rose by 14.2%, and free cash flow improved by EUR 209 million.
Why It Matters
The company's strong financial performance, particularly in revenue and EBITDA growth, indicates positive momentum in its Biopharma segment and improved cash flow generation.
Risk Assessment
Risk Level: low — This filing is a routine earnings report and does not contain any new material adverse information.
Key Numbers
- EUR 1,786M — Net Revenues (Q1 2025 net revenues increased by 7.4% cc.)
- 14.2% — Adj EBITDA (Adjusted EBITDA increased by 14.2%.)
- EUR 209M — Free Cash Flow (Free cash flow improved by EUR 209 million.)
Key Players & Entities
- Grifols, S.A. (company) — Registrant
- EUR 1,786 million (dollar_amount) — Net revenues for Q1 2025
- 7.4% (dollar_amount) — Net revenue growth for Q1 2025
- 14.2% (dollar_amount) — Adjusted EBITDA growth for Q1 2025
- EUR 209 million (dollar_amount) — Improvement in free cash flow for Q1 2025
- May 12, 2025 (date) — Date of earnings press release
FAQ
What was Grifols' net revenue for the first quarter of 2025?
Grifols' net revenue for the first quarter of 2025 reached EUR 1,786 million.
By what percentage did Grifols' Adjusted EBITDA increase in Q1 2025?
Grifols' Adjusted EBITDA increased by 14.2% in the first quarter of 2025.
How much did Grifols' free cash flow improve in Q1 2025?
Grifols' free cash flow improved by EUR 209 million in the first quarter of 2025.
Which segment drove the revenue growth for Grifols in Q1 2025?
The Biopharma segment drove the revenue growth, with a performance increase of 6.6% cc.
What was the like-for-like net revenue increase for Grifols in Q1 2025?
Like-for-like net revenues increased by 10.0% cc for Grifols in the first quarter of 2025.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 12, 2025 regarding Grifols SA (GIKLY).